Key facts: Altimmune appoints Jerry Durso as CEO; pemvidutide trial data pending

TradingView
2025.12.01 20:03
portai
I'm PortAI, I can summarize articles.

Altimmune, Inc. will see Jerry Durso become CEO on January 1, 2026, succeeding Vipin Garg, who will remain an advisor until June 30, 2026.123Altimmune's pemvidutide targets liver disease and weight loss. Mid-stage trial data is due soon, and an FDA meeting for a late-stage study is set for this year.4

  • Altimmune, Inc. will see Jerry Durso become CEO on January 1, 2026, succeeding Vipin Garg, who will remain an advisor until June 30, 2026.123
  • Altimmune's pemvidutide targets liver disease and weight loss. Mid-stage trial data is due soon, and an FDA meeting for a late-stage study is set for this year.4
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer